Robert Martin, MD
Surgical Oncology · Louisville, KYNPI 1619947504
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $397,020 of the $482,629 with a category attached, or 82.3%. Angiodynamics, Inc. accounts for 71.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $116,184 and has fallen 68.2% since, to $36,970 in 2025. Among surgical oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $1842.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$344K
- Eisai Inc.$52K
- Medical Device Business Services, Inc.$34K
- BK Medical Holding Company Inc.$13K
- Galil Medical Inc.$13K
- Biocompatibles, Inc.$7K
- plus $20K from 22 others
Across 86 payments — averaging $18,209 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Angiodynamics, Inc.$702K
- Merck$530K
- Varian Medical Systems, Inc.$75K
- ABK Biomedical USA, Inc.$67K
- Boston Scientific$62K
- Siemens Medical Solutions USA, Inc.$50K
- plus $79K from 4 others
What the payments were for
- Consulting fees$397,02082%
- Speaking & faculty fees$44,0989%
- Travel & lodging$33,3207%
- Food & beverage$8,1902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 94 | $344,296 |
| Eisai Inc. | 51 | $52,110 |
| Medical Device Business Services, Inc. | 22 | $34,352 |
| BK Medical Holding Company Inc. | 3 | $12,825 |
| Galil Medical Inc. | 8 | $12,665 |
| Biocompatibles, Inc. | 2 | $6,662 |
| Merck | 11 | $5,648 |
| Johnson & Johnson(2 entities) | 14 | $3,976 |
| AstraZeneca | 5 | $2,467 |
| Covidien LP | 1 | $2,375 |
| Healthmyne, Inc. | 2 | $1,847 |
| Sirtex Medical Inc | 1 | $1,750 |
| AbbVie | 16 | $329 |
| Medtronic | 3 | $294 |
| Galvanize Therapeutics, Inc | 1 | $214 |
| Siemens Medical Solutions USA, Inc. | 1 | $130 |
| Abbott | 7 | $128 |
| KARL Storz Endoscopy-america | 1 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $72 |
| Novo Nordisk | 4 | $71 |
| Alcresta Therapeutics, Inc. | 2 | $70 |
| Varian Medical Systems, Inc. | 1 | $64 |
| Astellas Pharma US Inc | 4 | $58 |
| Lexington Medical, Inc. | 1 | $47 |
| Bayer | 3 | $40 |
| Genentech, Inc. | 1 | $32 |
| Seagen Inc. | 1 | $16 |
| Acera Surgical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$233,691
- LENVIMA$51,742
- STRATAFIX$29,960
- ECHELON FLEX Stapler$25,510
- HARMONIC Product Family$25,510
- ICEFX$12,620
- THERASPHERE-BIO$6,600
- bk3000, bk3500 & bk5000 Ultrasound System$5,850
- Echelon Flex$5,525
- Harmonic$5,525
- SURGICEL NU-KNIT$3,395
- ETHICON$3,395
- CERTUS 140 MICROWAVE ABLATION SYSTEM$2,468
- IMFINZI$2,417
- SIR-Spheres Microspheres$1,750
- HealthMyne$1,750
- KEYTRUDA$738
- ALIYA SYSTEM$214
- LigaSure$153
- MicroThermX Microwave Ablation System$130
How this compares
$482,629 in reported general payments places this provider in the 95th percentile of 29 surgical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 50 | $213,759 |
| Pantoprazole Sodium | 61 | $3,770 |
| Omeprazole | 14 | $76 |
| Prednisone | 22 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $329 | $213,75950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 surgical oncology providers in Kentucky.
Other surgical oncology in Louisville
- Charles ScogginsLouisville$15K
- Nicolas AjkayLouisville$11K
- Prejesh PhilipsLouisville$9K
- Michael EggerLouisville$3K
- Amy QuilloLouisville$908
- Alissa DollLouisville$439
- Kelly McMastersLouisville$438
- Neal BhutianiLouisville$398
- Allison HatmakerLouisville$148
- Michael EdwardsLouisville$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.